Retatrutide for Knee Osteoarthritis: What the Phase 3 Data Shows

Introduction

For most patients with obesity-related knee osteoarthritis, treatment has meant managing symptoms rather than addressing root cause. NSAIDs take the edge off inflammation. Corticosteroid injections provide temporary relief. Physical therapy helps, but only if the underlying mechanical load on the joint is reduced. The fundamental driver — excess body weight — has historically been the hardest variable to change.

Retatrutide is the first medication to meaningfully close that gap. TRIUMPH-4, Eli Lilly's Phase 3 trial in adults with obesity and knee osteoarthritis, confirmed 28.7% average weight loss at 68 weeks — and alongside it, a 75.8% reduction in knee pain on the WOMAC scale at the 9mg dose. One in eight patients reported being completely free of knee pain by week 68.

These are not results from a pain medication. They are results from a weight loss drug — which is exactly what makes them clinically significant for a condition where mechanical load is the dominant driver of joint damage.

This article covers what TRIUMPH-4 tested, what it found, how the results compare to current OA treatments, and what they mean for patients who are waiting.

Why Obesity and Knee OA Are Linked

Knee osteoarthritis is not simply a disease of aging or genetics — it is profoundly mechanical. Excess weight places chronic, repetitive stress on cartilage that cannot repair itself after damage. The relationship is biomechanically precise: each kilogram of body weight lost reduces the compressive load on the knee joint by approximately 4 kg during walking. For a patient losing 32 kg on retatrutide, that translates to roughly 128 kg less pressure per step.

Beyond mechanics, adipose tissue itself is inflammatory. Fat cells produce cytokines — including IL-6, TNF-alpha, and leptin — that drive systemic and local joint inflammation independent of mechanical loading. Patients with obesity and OA therefore carry two compounding burdens: structural damage from load and biological inflammation that accelerates cartilage loss and amplifies pain.

This is why weight loss is the most evidence-based non-surgical intervention for knee OA. Clinical guidelines consistently recommend 10% or more total body weight loss for meaningful OA symptom improvement. Retatrutide produces nearly three times that threshold.

TRIUMPH-4: What It Was Designed to Test

TRIUMPH-4 was a Phase 3, randomized, double-blind, placebo-controlled trial specifically designed to evaluate retatrutide in adults with two simultaneous conditions: obesity and knee osteoarthritis.

The fact that WOMAC pain was a co-primary endpoint — not a secondary or exploratory outcome — is important. Lilly had to demonstrate both meaningful weight loss AND meaningful joint pain reduction for the trial to succeed. TRIUMPH-4 was not a post-hoc observation. It was a pre-specified hypothesis that treating obesity with retatrutide would simultaneously and independently improve knee OA symptoms.

Weight Loss Results

Both doses met the weight loss co-primary endpoint:

For context: clinical guidelines for OA recommend 10% weight loss as a meaningful threshold for joint symptom improvement. The average retatrutide patient at 12mg lost nearly three times that threshold.

Pain Results: WOMAC Score

WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) is the validated instrument for measuring joint pain, stiffness, and function in OA. The pain subscale runs from 0 (no pain) to 10 (worst pain), with a baseline of 6.0 in TRIUMPH-4 participants.

Both retatrutide doses produced clinically and statistically significant pain reductions:

Percent reductions are from a post-hoc analysis using the efficacy (on-treatment) estimand. The pre-specified co-primary endpoint used absolute point change; both doses met superiority vs placebo.

The placebo group's 40.3% pain reduction is substantial and reflects a well-documented placebo effect in OA trials, plus natural history improvement from lifestyle counseling. Retatrutide produced an incremental ~35 percentage points of additional pain reduction beyond what placebo achieved — representing the drug's specific therapeutic contribution.

The 9mg dose achieved slightly higher pain reduction than 12mg (75.8% vs 73.3%), despite lower weight loss. This is not unusual in clinical trials with complex pain endpoints and reflects natural variation. Both results are clinically meaningful.

Physical Function Results

WOMAC physical function subscale (baseline 5.8 points, scale 0–10):

Both retatrutide doses produced reductions in the physical function subscale exceeding 70% — meaning patients could perform daily activities with substantially less difficulty than at baseline.

6-Minute Walk Test: A direct measure of functional capacity — participants walked 63 meters further in 6 minutes after 68 weeks of retatrutide treatment, compared to 12 meters further in the placebo group. A 51-meter improvement beyond placebo is clinically significant for a population with chronic joint pain limiting mobility.

IWQOL-Lite (Impact of Weight on Quality of Life): +25 points with retatrutide vs +5 points with placebo — a 20-point additional improvement in weight-related quality of life.

Pain-Free Outcomes

In a post-hoc analysis at week 68:

• 14.1% of patients on retatrutide 9mg reported being completely free of knee pain
• 12.0% of patients on retatrutide 12mg reported being completely free of knee pain
• 4.2% of patients on placebo reported being completely free of knee pain

Approximately 1 in 8 retatrutide-treated patients became pain-free in a population that entered the trial with confirmed moderate-to-severe osteoarthritis. For a non-surgical pharmacological intervention, that is a meaningful outcome that will matter to patients and clinicians when making prescribing decisions.

The Mechanism: How Losing 70 Pounds Changes What Happens in the Knee

The results raise an obvious question: is the pain reduction simply from weight loss, or does retatrutide have additional direct effects on the joint?

The evidence suggests both mechanisms contribute, with mechanical unloading as the primary driver.

Mechanical: At 32.3 kg average weight loss (12mg), TRIUMPH-4 participants removed approximately 130 kg (286 lbs) of compressive load from each knee with every step. This directly reduces the mechanical stress on damaged cartilage, alleviates synovial fluid compression, and allows periarticular structures to decompress.

Inflammatory: Adipose tissue reduction lowers systemic levels of pro-inflammatory cytokines (IL-6, TNF-alpha, leptin) that drive OA progression. Weight loss is a systemic anti-inflammatory intervention. GLP-1 receptor agonism may additionally have direct anti-inflammatory effects, though this is less established for the OA-specific pathway.

The placebo group insight: Placebo participants lost only 2.1% of body weight but still experienced 40.3% WOMAC pain reduction — attributable largely to trial participation, lifestyle counseling, and placebo response. This underscores that the incremental 35-percentage-point gap between retatrutide and placebo reflects genuine pharmacological benefit on top of what behavioral changes alone can produce.

Safety Profile in TRIUMPH-4

The GI side effect profile is consistent with the GLP-1 drug class and peaks during the dose escalation phase (weeks 1–16). Dysesthesia — abnormal skin sensations unique to retatrutide — occurred in 8.8% at 9mg and 20.9% at 12mg. Most cases were mild and rarely led to discontinuation.

Relevant for OA patients: the 9mg dose produced nearly comparable pain reduction (75.8% vs 73.3%) with substantially lower dysesthesia incidence (8.8% vs 20.9%). For OA patients where pain relief is the primary goal and they've already achieved meaningful weight loss at 9mg, staying at the lower dose is a clinically reasonable strategy.

How These Results Compare to Current OA Treatments

All values in the table represent improvement from baseline and include natural history, lifestyle counseling, and placebo effect. TRIUMPH-4's placebo group achieved 40.3% pain reduction from baseline — unusually high, reflecting trial participation effects. Retatrutide's treatment-specific effect above placebo was approximately 35 percentage points. Cross-trial comparisons use different populations, designs, and measurement approaches.

The comparison is striking. Retatrutide's pain reduction is in the same range as total knee replacement — but without surgery, without anesthesia, and without permanence. It dramatically outperforms every currently approved pharmacological option for OA pain.

The important caveat: these are cross-trial comparisons with different populations, designs, and endpoints. TRIUMPH-4 enrolled participants with obesity, while many OA trials enroll broader populations. Direct head-to-head comparisons don't exist. But the magnitude of the effect in TRIUMPH-4 is genuinely distinctive.

Availability and FDA Indication

Retatrutide is not yet FDA-approved. Based on TRIUMPH-4's results and the completed TRIUMPH-1 general obesity trial (28.3% weight loss in 2,339 patients, May 2026), Eli Lilly is expected to submit a New Drug Application in Q4 2026.

Lilly's NDA will likely include obesity as the primary indication, with knee osteoarthritis as a separate label indication — a meaningful distinction that could influence insurance coverage pathways for OA patients who might not qualify on obesity grounds alone.

Expected FDA review: 2027. Commercial launch: Q1–Q2 2028.

For a complete overview of the retatrutide approval timeline, see our FDA approval timeline guide.

For the full side effect profile including management strategies, see our complete side effects guide.

Conclusion

TRIUMPH-4 established what obesity medicine researchers had hypothesized but never confirmed at Phase 3 scale: that pharmacological weight loss at sufficient magnitude can produce OA pain reduction approaching what surgical treatment achieves.

28.7% weight loss and 75.8% WOMAC pain reduction were not achieved through separate interventions. They were achieved through a single weekly injection. That simultaneity — treating the metabolic root cause while the structural problem improves as a consequence — is what makes retatrutide potentially transformative for OA patients.

The 9mg dose deserves particular attention for OA patients: 75.8% pain reduction at half the dysesthesia burden of 12mg (8.8% vs 20.9%), with 26.4% average weight loss. For patients where joint pain relief is the primary goal, the 9mg dose may prove the optimal choice.

The wait until 2028 is real. For OA patients who cannot or will not undergo surgery and have failed conventional pharmacological management, it may be worth it.

Sources

• Healio: "Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain." December 11, 2025. (Reporting TRIUMPH-4 topline results)
• Rheumatology Advisor: "TRIUMPH-4 Results: Retatrutide Cuts Weight and Knee OA Pain." December 17, 2025. (Citing Lilly press release and WOMAC data)
• Patient Care Online: "Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial." 2025.
• Lilly Medical: Preliminary results from TRIUMPH-4 (official medical information, lilly.com). December 2025.
• Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026;28(1):83-93.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.